|
1
|
Ahmed GM, Abed MN and Alassaf FA: Impact
of calcium channel blockers and angiotensin receptor blockers on
hematological parameters in type 2 diabetic patients. Naunyn
Schmiedebergs Arch Pharmacol. 397:1817–1828. 2024.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Alnaser RI, Alassaf FA and Abed MN:
Melatonin as a potential treatment option in diabetes
complications. Eur J Transl Clin Med: 7, 2024
doi:10.31373/ejtcm/192108.
|
|
3
|
Antwi-Baffour S, Kyeremeh R, Boateng SO,
Annison L and Seidu MA: Haematological parameters and lipid profile
abnormalities among patients with Type-2 diabetes mellitus in
Ghana. Lipids Health Dis. 17(283)2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Singh DK, Winocour P and Farrington K:
Erythropoietic stress and anemia in diabetes mellitus. Nat Rev
Endocrinol. 5:204–210. 2009.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Ebrahim H, Fiseha T, Ebrahim Y and
Bisetegn H: Comparison of hematological parameters between type 2
diabetes mellitus patients and healthy controls at Dessie
comprehensive specialized hospital, Northeast Ethiopia: Comparative
cross-sectional study. PLoS One. 17(e0272145)2022.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Sahay M, Kalra S, Badani R, Bantwal G,
Bhoraskar A, Das AK, Dhorepatil B, Ghosh S, Jeloka T, Khandelwal D,
et al: Diabetes and anemia: International diabetes federation
(IDF)-Southeast asian region (SEAR) position statement. Diabetes
Metab Syndr. 11 (Suppl):S685–S695. 2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Alnaser RI, Alassaf FA and Abed MN:
Adulteration of hypoglycemic products: The silent threat. Rom J Med
Pract. 18:202–205. 2023.
|
|
8
|
Bunn HF: Erythropoietin. Cold Spring Harb
Perspect Med. 3(a011619)2013.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Ahmed GM, Alassaf FA and Abed MN: The
interplay of the angiotensin receptor blockers and haematological
abnormalities: Insights and implications. J Ayub Med Coll
Abbottabad. 35 (Suppl 1)):S785–S792. 2023.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Bell DSH: Metformin-induced vitamin B12
deficiency can cause or worsen distal symmetrical, autonomic and
cardiac neuropathy in the patient with diabetes. Diabetes Obes
Metab. 24:1423–1428. 2022.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Ahmed G, Abed M and Alassaf F: An overview
of the effects of Sodium-glucose Cotransporter-2 inhibitors on
hematological parameters in diabetic patients. Iraqi J Pharm:
65-71, 2023 doi:10.33899/iphr.2023.137946.1041.
|
|
12
|
Zeng L, Chan GCK, Ng JKC, Fung WWS, Chow
KM and Szeto CC: The effect of Dipeptidyl peptidase 4 (DPP-4)
inhibitors on hemoglobin level in diabetic kidney disease: A
retrospective cohort study. Medicine (Baltimore).
102(e34538)2023.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Broxmeyer HE, Hoggatt J, O'Leary HA,
Mantel C, Chitteti BR, Cooper S, Messina-Graham S, Hangoc G, Farag
S, Rohrabaugh SL, et al: Dipeptidylpeptidase 4 negatively regulates
colony-stimulating factor activity and stress hematopoiesis. Nat
Med. 18:1786–1796. 2012.PubMed/NCBI View
Article : Google Scholar
|
|
14
|
Alassaf FA, Jasim MHM, Alfahad M, Qazzaz
ME, Abed MN and Thanoon IAJ: Effects of bee propolis on FBG, HbA1c,
and insulin resistance in healthy volunteers. Turkish J Pharm Sci.
18:405–409. 2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Al-dabbagh BM, Abed MN, Mahmood NM,
Alassaf FA, Jasim MH, Alfahad MA and Thanoon IAJ:
Anti-inflammatory, antioxidant and hepatoprotective potential of
milk thistle in albino rats. Lat Am J Pharm. 41:1832–1841.
2022.
|
|
16
|
Abed MN, Qazzaz ME and Alassaf FA:
Investigating the nephrotoxic effects of medroxyprogesterone in
female albino rats. Ukr J Nephrol Dial. 2:25–33. 2024.
|
|
17
|
Imad AJT, Jasim MHM and Mohammed N:
Effects of omega-3 on renal function tests and uric acid level in
healthy volunteers. Lat Am J Pharm. 40:2319–2323. 2021.
|
|
18
|
Arnolds S, Dellweg S, Clair J, Dain MP,
Nauck MA, Rave K and Kapitza C: Further improvement in postprandial
glucose control with addition of exenatide or sitagliptin to
combination therapy with insulin glargine and metformin. Diabetes
Care. 33:1509–1515. 2010.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Dong H, Sun Y, Nie L, Cui A, Zhao P, Leung
WK and Wang Q: Metabolic memory: Mechanisms and diseases. Signal
Transduct Target Ther. 9(38)2024.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Cozma GV, Apostu A, Macasoi I, Dehelean
CA, Cretu OM, Dinu S, Gaiță D and Manea A: In vitro and in ovo
evaluation of the potential hepatoprotective effect of metformin.
Medicina (Kaunas). 58(705)2022.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Ahmed A, Omar Z, El-Bakry MH and Ahmed MA:
Hepatoprotective effect of dipeptidyl peptidase-4 inhibitor
sitagliptin against carbon tetrachloride-induced liver fibrosis in
mice. Al-Azhar Assiut Med J. 19:459–468. 2021.
|
|
22
|
Jiang W, Wen D, Cheng Z, Yang Y, Zheng G
and Yin F: Effect of sitagliptin, a DPP-4 inhibitor, against
DENA-induced liver cancer in rats mediated via NF-κB activation and
inflammatory cytokines. J Biochem Mol Toxicol.
32(e22220)2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Wang X, Ke J, Zhu YJ, Cao B, Yin RL, Wang
Y, Wei LL, Zhang LJ, Yang LY and Zhao D: Dipeptidyl peptidase-4
(DPP4) inhibitor sitagliptin alleviates liver inflammation of
diabetic mice by acting as a ROS scavenger and inhibiting the NFκB
pathway. Cell Death Discov. 7(236)2021.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Alnaser RI, Alassaf FA and Abed MN:
Incretin-based therapies: A promising approach for modulating
oxidative stress and insulin resistance in sarcopenia. J Bone
Metab. 31:251–263. 2024.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Abed MN, Alassaf FA and Qazzaz ME:
Exploring the interplay between vitamin D, insulin resistance,
obesity and skeletal health. J Bone Metab. 31:75–89.
2024.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Maeda H, Kubota A, Kanamori A, Tanaka Y,
Terauchi Y and Matsuba I: Study Group of Diabetes Committee,
Kanagawa Physicians Association. Effects of sitagliptin on the
serum creatinine in Japanese type 2 diabetes. Diabetes Res Clin
Pract. 108:e42–e45. 2015.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Tonneijck L, Smits MM, Muskiet MHA,
Hoekstra T, Kramer MHH, Danser AHJ, Diamant M, Joles JA and van
Raalte DH: Acute renal effects of the GLP-1 receptor agonist
exenatide in overweight type 2 diabetes patients: A randomised,
double-blind, placebo-controlled trial. Diabetologia. 59:1412–1421.
2016.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Kutoh E, Wada A, Kuto AN, Hayashi J and
Kurihara R: Link between serum uric acid and pancreatic beta-cell
function in drug naïve subjects with type 2 diabetes treated with
sitagliptin. Hosp Pract (1995). 49:71–78. 2021.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Donnelly LA, Dennis JM, Coleman RL, Sattar
N, Hattersley AT, Holman RR and Pearson ER: Risk of anemia with
metformin use in Type 2 diabetes: A MASTERMIND study. Diabetes
Care. 43:2493–2499. 2020.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Merdin FA and Merdin A: Do DPP-4 enzyme
inhibitors affect hemoglobin, leucocyte and thrombocyte levels in
patients with type 2 diabetes mellitus? Eur Rev Med Pharmacol Sci.
27:4614–4618. 2023.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Cullis JO, Fitzsimons EJ, Griffiths WJ,
Tsochatzis E and Thomas DW: Investigation and management of a
raised serum ferritin. Br J Haematol. 181:331–340. 2018.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Mahroum N, Alghory A, Kiyak Z, Alwani A,
Seida R, Alrais M and Shoenfeld Y: Ferritin-from iron, through
inflammation and autoimmunity, to COVID-19. J Autoimmun.
126(102778)2022.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Anandhan A, Dodson M, Shakya A, Chen J,
Liu P, Wei Y, Tan H, Wang Q, Jiang Z, Yang K, et al: NRF2 controls
iron homeostasis and ferroptosis through HERC2 and VAMP8. Sci Adv.
9(ade9585)2023.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Oh Y and Jun HS: Effects of glucagon-like
peptide-1 on oxidative stress and Nrf2 signaling. Int J Mol Sci.
19(26)2017.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Durante W: Targeting heme Oxygenase-1 in
the arterial response to injury and disease. Antioxidants (Basel).
9(829)2020.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Abdel-Gaber SA, Geddawy A and Moussa RA:
The hepatoprotective effect of sitagliptin against hepatic ischemia
reperfusion-induced injury in rats involves Nrf-2/HO-1 pathway.
Pharmacol Rep. 71:1044–1049. 2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Genc FT, Nalbant A, Genc AC and Kaya T:
Effect of a combination of gliptin and metformin on serum vitamin
B12, folic acid, and ferritin levels. Rev Assoc Med Bras (1992).
69(e20230641)2023.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Moreira AC, Mesquita G and Gomes MS:
Ferritin: An inflammatory player keeping iron at the core of
Pathogen-host interactions. Microorganisms. 8(589)2020.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Farag SS, Nelson R, Cairo MS, O'Leary HA,
Zhang S, Huntley C, Delgado D, Schwartz J, Zaid MA, Abonour R, et
al: High-dose sitagliptin for systemic inhibition of
dipeptidylpeptidase-4 to enhance engraftment of single cord
umbilical cord blood transplantation. Oncotarget. 8:110350–110357.
2017.PubMed/NCBI View Article : Google Scholar
|
|
40
|
O'Leary HA, Capitano M, Cooper S, Mantel
C, Boswell HS, Kapur R, Ramdas B, Chan R, Deng L, Qu CK and
Broxmeyer HE: DPP4 truncated GM-CSF and IL-3 manifest distinct
receptor-binding and regulatory functions compared with their
full-length forms. Leukemia. 31:2468–2478. 2017.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Ropa J and Broxmeyer HE: An expanded role
for dipeptidyl peptidase 4 in cell regulation. Curr Opin Hematol.
27:215–224. 2020.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Aono M and Sato Y: Dipeptidyl peptidase 4
inhibitor linagliptin can decrease the dosage of
erythropoiesis-stimulating agents in patients on hemodialysis. Ren
Replace Ther. 2(44)2016.
|
|
43
|
Hasegawa T, Zhao J, Bieber B, Zee J,
Pisoni RL, Robinson BM, Hanafusa N and Nangaku M: Association
between dipeptidyl Peptidase-4 inhibitor prescription and
Erythropoiesis-stimulating agent hyporesponsiveness in hemodialysis
patients with diabetes mellitus. Kidney Blood Press Res.
46:352–361. 2021.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Jin P, Kang J, Lee MK and Park JW:
Ferritin heavy chain controls the HIF-driven hypoxic response by
activating the asparaginyl hydroxylase FIH. Biochem Biophys Res
Commun. 499:475–4781. 2018.PubMed/NCBI View Article : Google Scholar
|
